IRX-2 (citoplurikin) Phase I/II testing was performed at Mexico's National Cancer Institute (INCAN). In those trials, safety, dosing, and route of administration were tested. IRX-2 was well tolerated, demonstrated no adverse events, and most importantly, demonstrated significant activity in stimulating T-cell-led tumor rejection.
Using oncology endpoints of clinical response, IRX-2 demonstrated a 38% overall tumor response rate. The table below presents 32 of the 42 patients where both pre- and post-surgery measurements of the tumor were available:
| Category |
Description |
Number of Patients |
% of Total |
| Complete Response |
Complete disappearance |
2 |
6.3 |
| Partial Response |
³
50% decrease |
10 |
31.2 |
| Overall Response |
Complete and Partial Response |
12 |
37.5 |
| Non Response |
<50% decrease |
20 |
62.5 |
| |
|
32 |
100.0 |
|
|
| 
